1. Introduction {#sec1-molecules-23-01315}
===============

The process of aging has hastened the increasing number of elderly people in human society. In the meantime, the risk of cerebrovascular disease increases year by year. Among cerebrovascular disease, ischemic cerebrovascular disease is one of the diseases with the highest morbidity, which has the features of high incidence, high morbidity, and high mortality \[[@B1-molecules-23-01315]\]. Cerebral ischemic infarction can cause disability, cognitive dysfunction, vascular dementia, and even death. The increasing morbidity and mortality of cerebral ischemia seriously affects the physical and mental health of the elderly, as well as an unbearable financial toll for both society and families \[[@B2-molecules-23-01315]\].

When ischemic cerebrovascular disease attacks, the priority goal is to recover the blood supply of the brain as soon as possible to avoid brain tissue necrosis. However, if the treatment is not timely, cerebral ischemia reperfusion injury will occur. Therefore, ischemic cerebrovascular patients should be evaluated rapidly in the early phase to receive timely and appropriate treatment. Unfortunately, the diagnostic features of the ischemic cerebrovascular are still limited. Typical diagnosis relies upon medical equipment, such as computed tomography (CT) or magnetic resonance imaging (MRI), but these examinations are time-consuming and costly. Therefore, it is necessary to develop novel biomarkers through blood metabolomics for the diagnosis and prognosis of ischemic cerebrovascular \[[@B3-molecules-23-01315]\].

Till now, the mechanisms for ischemic cerebrovascular have been dramatically elucidated and considered a series of complex pathophysiological processes, including energy metabolism disorder, toxicity of excitatory amino acids, overloaded intracellular calcium, increase of oxygen free radicals, endothelial cells injury, apoptosis gene activation and inflammatory response \[[@B4-molecules-23-01315],[@B5-molecules-23-01315],[@B6-molecules-23-01315],[@B7-molecules-23-01315]\], but the metabolite profiling of ischemic cerebrovascular disease remains unknown. Therefore, the study of the metabolic variations might be expected to provide new insights into the pathogenesis of ischemic cerebrovascular disease.

The other major challenge for ischemic cerebrovascular disease is that no effective and generally accepted medicine is available except for tissue-type plasminogen activator (t-PA ) \[[@B8-molecules-23-01315]\]. Unfortunately, the clinical application of t-PA is limited because of the symptomatic intracerebral hemorrhage adverse reaction and narrow therapeutic window. Increasing amounts of evidence in treating ischemic cerebrovascular disease demonstrate that treatment regimens containing multiple drugs lead to maximal therapeutic efficacy with minimal adverse effects. Therefore, combination therapy becomes a rational and promising choice, and has been advocated in traditional Chinese medicine (TCM) to prevent and cure ischemic cerebrovascular disease for thousands of years. Varieties of herbal formulae or extracts have been shown to exhibit anti-cerebral ischemic effects, and Kudiezi injection (KDZI) is one of the most representative ones. KDZI, also known as Diemailing injection, is a TCM injection of the composite plant *Ixeris sonchifolia Hance* (also known as Kudiezi) \[[@B9-molecules-23-01315]\]. KDZI contains flavonoids, adenosine, sesquiterpene lactones, and triterpenoid saponins, etc. \[[@B10-molecules-23-01315],[@B11-molecules-23-01315]\]. Studies have shown that KDZI can inhibit thrombosis, increase fibrinolytic activity, dilate blood vessels, reduce vascular resistance, and increase brain and blood flow \[[@B12-molecules-23-01315]\]. KDZI also has protective effect on brain injury in rats with cerebral ischemia reperfusion, but the mechanism is not clear yet \[[@B13-molecules-23-01315],[@B14-molecules-23-01315],[@B15-molecules-23-01315],[@B16-molecules-23-01315]\]. Systemic studies are, therefore, required to provide a comprehensive evaluation of the efficacy of KDZI.

Metabolomics, an important part of systemic biology, was initially defined by professor Nicholson et al. \[[@B17-molecules-23-01315]\]. Metabolomics aims at comprehensive characterization of the total metabolome in a biological system and the responses that dynamic metabolomics response to alterations of inner and external factors \[[@B18-molecules-23-01315],[@B19-molecules-23-01315]\]. In recent years, metabolomics has been widely used in the diagnosis of heart disease \[[@B20-molecules-23-01315]\], diabetes mellitus \[[@B21-molecules-23-01315]\], and cancer \[[@B22-molecules-23-01315]\]. However, the plasma metabolic profiling of ischemic cerebrovascular remains poorly understood and no metabolomic assessment of the anti-cerebral ischemia effects of KDZI is published.

In this study, a middle cerebral artery occlusion reperfusion (MCAO/R) rat model was established to mimic ischemic cerebrovascular, and plasma samples were collected from the MCAO/R rat model, controls, sham surgery group, and KDZI-treated group, an ultra-performance liquid chromatography-high resolution mass spectrometry (UPLC-HRMS)-based metabolomics approach was developed to characterize the metabolic biomarkers on ischemic cerebrovascular, and to discover potential targets of KDZI on ischemic cerebrovascular treatment. Partial least squares-discriminant analysis (PLS-DA) was further utilized to identify the ischemic cerebrovascular-related metabolic alterations and investigate the anti-cerebral ischemia mechanisms of KDZI. In addition, the study provided a reasonable basis for clinical treatment programs and a scientific example to highlight the power of the LC-HRMS system for sophisticated biological datasets.

2. Results {#sec2-molecules-23-01315}
==========

2.1. Effects of KDZI on Pathological Brain Morphology Alterations in MCAO/R Rats {#sec2dot1-molecules-23-01315}
--------------------------------------------------------------------------------

Hematoxylin and eosin (HE) staining ([Figure 1](#molecules-23-01315-f001){ref-type="fig"}A) showed that no neuronal damage or inflammatory cell infiltration was observed in the cerebral cortex of rats in Sham group, the number and morphology of neuronal cells were normal, and the cell membrane and nucleolus were clear. However, the ischemic cortex of the brains in MCAO/R rats displayed cytoclasis, karyopyknosis, and neuronal cells were reduced. After seven days of KDZI administration, brain edema was significantly alleviated, neuronal cells almost returned to normal, and the structure became clear and integral.

2.2. Effects of KDZI on Infarct Size in MCAO/R Model Rats {#sec2dot2-molecules-23-01315}
---------------------------------------------------------

As shown in [Figure 1](#molecules-23-01315-f001){ref-type="fig"}B,C, the results of 2,3,5-triphenyltetrazolium chloride (TTC) staining demonstrated that the relative area ratio of the infarcted area of rats in the model group was 0.232, which was statistically significant (compared with rats in the sham group, *p* \< 0.01), indicating that the MCAO/R model was successfully established. Compared with the MCAO/R group, the relative ratio of the infarcted area of rats in the KDZI administration group was 0.108, indicating that the KDZI significantly reduced the infarct size. The results indicated that KDZI can significantly reduce the cerebral infarction size and ameliorate cerebral ischemia.

2.3. Metabolic Profiling of Plasma Sample {#sec2dot3-molecules-23-01315}
-----------------------------------------

To analyze the profile of the metabolites, the signal responses of plasma metabolites in ESI^+^ and ESI^-^ modes were combined. Both ESI^+^ and ESI^-^ displayed obvious differences in the metabolite profile in the plasma samples, indicating that the combination of positive and negative modes can be used to analyze plasma metabolism to a certain degree.

The quality control (QC) samples were used in the optimization of separation and determination conditions. The typical base peak intensity chromatograms of plasma samples, obtained in ESI^+^ and ESI^-^ under the optimized conditions, are presented in [Figure 2](#molecules-23-01315-f002){ref-type="fig"}. Some distinctly different peaks between the sham group and the ischemia model group were found in the base peak intensity chromatograms and were then highlighted. The precision and repeatability of the system were evaluated by the reduplicate analysis of six injections of the same QC sample. The relative standard deviation (*RSD*) of retention times (t~R~) and peak intensities for the selected ions from QC samples were calculated to evaluate the method performance.

As shown in [Table 1](#molecules-23-01315-t001){ref-type="table"}, the *RSD* of the retention times for precision, stability and repeatability were 0.035--0.25%, 0.09--1.88%, and 0.04\~0.59% in positive ion mode and 0.03--0.65%, 0.07--0.56%, and 0.08--0.56% in negative ion mode; the *RSD* of the peak intensities for precision, stability, and repeatability were 3.41--7.10%, 3.72--7.70%, and 4.52--6.98% in positive ion mode and 2.91--7.33%, 2.30--7.07%, and 3.45--8.33% in negative ion mode. The results of the precision, stability, and repeatability demonstrates that the proposed method is a robust method and the analysis in the study is satisfied.

2.4. Multivariate Data Analysis of UPLC-LTQ/Orbitrap Data {#sec2dot4-molecules-23-01315}
---------------------------------------------------------

TTC and HE stainings showed that the injury of cerebral ischemia-reperfusion of rats with treatment of KDZI was significantly improved compared with that of the MCAO/R group, so we used non-targeted LC-MS to detect the anti-ischemia mechanism of KDZI. Firstly, based on the ANOVA test, we found a total of 449 ions changed significantly (*p* \< 0.05) between MCAO/R and sham groups. The ions with statistical significance were merged and introduced into SIMCA-P for multivariate analyses. According to the PCA model shown in [Figure 3](#molecules-23-01315-f003){ref-type="fig"}A,E, there was a good separation among sham, MCAO/R, and KDZI groups, the R2X(cum) value were 0.71 in ESI^+^ and 0.647 in ESI^−^ mode, respectively, which indicated that acute ischemia reperfusion and the intervention of KDZI can cause significant changes in the related components.

In order to examine the possible influence on the metabolic pattern of KDZI, and to verify the metabolic features of MCAO/R, the supervised method PLS-DA was used to isolate the variables that were responsible for differences among three groups. In ESI^+^ mode, R2X(cum) = 0.797, R2Y(cum) = 0.989; in ESI^−^ mode, R2X(cum) = 0.657, and R2Y(cum) = 0.949 ([Figure 3](#molecules-23-01315-f003){ref-type="fig"}B,F). The loading S-plot shown in [Figure 3](#molecules-23-01315-f003){ref-type="fig"}C,G explains the separation above and is used to discover biomarkers between the three groups. Furthermore, the robustness of the PLS-DA models was assessed by a 200-times permutation test. No over-fitting (Q2Y \> 0.5) was observed according to the results of the permutation test ([Figure 3](#molecules-23-01315-f003){ref-type="fig"}D,H) \[[@B23-molecules-23-01315]\].

2.5. Identification of Metabolites {#sec2dot5-molecules-23-01315}
----------------------------------

As illustrated by PLS-DA plot, 210 ions were selected (VIP\> 1) for chemical structure identification, which contributed to the good separation of sham, MCAO/R, and KDZI rats. Based on the published strategy \[[@B24-molecules-23-01315],[@B25-molecules-23-01315]\], the following steps were performed for the identification of chemical structures in this study. The quasi-molecular ions were confirmed and the exact masses of the monoisotopic molecular weights were used to search reliable online databases such as the Human Metabolome Database \[[@B26-molecules-23-01315]\] and Metlin \[[@B27-molecules-23-01315]\]. The MS/MS spectra were analyzed to confirm the structure of the identified metabolites by the Mass Bank \[[@B28-molecules-23-01315]\] and Lipidbank \[[@B29-molecules-23-01315]\]. Identification of MS/MS using the mzCloud database, and the structures of the compounds were identified through manual comparison. Compound Discoverer 2.0 software (ThermoFisher Scientific Inc, USA) matches the mzCloud spectra of MS^1^ and MS^2^ mass spectrum data with accurate molecular weight. The parameters are MS^1^ mass accuracy \<5 ppm and the library search algorithm is HighChem Low + High Res. The score matching threshold is greater than, or equal to, 60 (the higher the matching is, the more accurate it is 100). During the search process, isotope matching and deduction of background noise (S/N ratio \< 10,000 is cutoff) are performed.

Subsequently, 32 metabolites were identified. The names of the biomarkers, the related enzymes and the related metabolic pathways are presented in [Table 2](#molecules-23-01315-t002){ref-type="table"}. Among them, the levels of taurochenodesoxycholic acid, leucine, l-phenylalanine, l-tryptophan, arachidonic acid, and PE were significantly decreased in the MCAO/R group, compared with the sham group, after seven days of KDZI administration, the compounds mentioned above were increased. In contrast, the level of l-valine and 5-hydroxyindole-3-acetic acid (5-HIAA) in the plasma of the MCAO/R group were increased, and KDZI decreased the contents of [l]{.smallcaps}-valine and 5-HIAA in plasma (*p* \< 0.05).

In addition, the hierarchical cluster analysis was performed to assess the relatedness and the distance of samples in different groups, and the heatmap was presented as a visual aid by using those biomarkers as variables. On the y-axis, the cluster was broken into three parts, including the sham group, MCAO/R group, and MCAO + KDZI ([Figure 4](#molecules-23-01315-f004){ref-type="fig"}).

2.6. Structure Identification {#sec2dot6-molecules-23-01315}
-----------------------------

In this study, a total of 32 compounds were identified in rats' plasma. [l]{.smallcaps}-phenylalanine was used as an example to elucidate its structure. In HESI positive mode, a \[M + H\]^+^ peak could be observed, the retention time of [l]{.smallcaps}-phenylalanine was 2.829 min, and the *m*/*z* was 166.08665 (mass error −2.4 ppm). Fragment ions of *m*/*z* 148.92, *m*/*z* 130.92, *m*/*z* 119.92, and *m*/*z* 117 appeared in MS^2^ by LTQ-Orbitrap mass. The peak of *m*/*z* 119.92 appeared in the form of base peak in the MS^2^ spectrum, which differed from the peak of the excimer ion by 46 Da and one molecule of formic acid, so it was presumed to be a carboxylic acid compound. In addition, both the excimer ions and the main fragments were even numbers. The compound is presumed to be a nitrogen-containing compound. Additionally, *m*/*z* 148.92 was a fragment ion of an excimer ion-missing NH~2~, which was identified as phenylalanine by comparison with databases, such as Metlin and HMDB. The mass spectrogram and the cleavage behavior are shown in [Figure 5](#molecules-23-01315-f005){ref-type="fig"}A,B. The identifications of other compounds are the same as above.

2.7. Metabolic Pathway Analysis {#sec2dot7-molecules-23-01315}
-------------------------------

On the basis of the identified compounds and the Kyoto Encyclopedia of Genes and Genomes online database of metabolic pathways \[[@B30-molecules-23-01315]\], a map of metabolic pathways of the treatment of cerebral ischemia-reperfusion injury with KDZI was constructed, shown in [Figure 6](#molecules-23-01315-f006){ref-type="fig"} and [Table 3](#molecules-23-01315-t003){ref-type="table"}. The relevant metabolic pathways and corresponding *p*-values and *FDR* correction (FDR correction value of the *p*-value) are shown in [Table 3](#molecules-23-01315-t003){ref-type="table"} and [Figure 6](#molecules-23-01315-f006){ref-type="fig"}. Among them, tryptophan metabolism, valine, leucine, and isoleucine degradation, and valine, leucine, and isoleucine biosynthesis were the major relevant metabolic pathways. Tryptophan, valine, leucine, and isoleucine were important factors related to cerebral ischemia.

3. Discussion {#sec3-molecules-23-01315}
=============

3.1. Characterized Potential Biomarkers {#sec3dot1-molecules-23-01315}
---------------------------------------

Cerebral ischemic infarction can cause disability, cognitive dysfunction, vascular dementia and even death. The increasing morbidity and mortality of cerebral ischemia seriously affects the physical and mental health of the elderly, as well as delivering an unbearable financial toll on society and families. Therefore, it is better to find serum biomarkers as compared to physical diagnosis, such as CT, as early as possible before the ischemic injury. Hence, we designed this study to find biomarkers of cerebral ischemia reperfusion by using metabolomics technology. In this research, we found that KDZI had the effect of reducing embolism area of MCAO/R rats and regulating of metabolites relevant to cerebral ischemia reperfusion. 32 potential biomarkers were found in plasma in the process. To date, metabolites of ischemic cerebral reperfusion rats with the treatment of Kudiezi injection have been analyzed using UHPLC-LTQ-Orbitrap, but only 15 metabolites were found in their study \[[@B31-molecules-23-01315]\].

We observed taurochenodesoxycholic acid (TCDCA) were increased after KDZI administration to MCAO/R rats. In the studies of excitatory neurotoxicity and hypoxia, TCDCA can maintain the function of mitochondria, decrease the calcium influx triggered by glutamate neurotoxicity, and protect nerve function. Taurine interacts with gamma-aminobutyric acid (GABA) to activate GABA receptors and glycine receptors, enhance the neuroprotective effects, assist in the transport of ions, like Ca^2+^, Mg^2+^, Na^+^, and K^+^, and to maintain normal osmotic pressure intracellularly and extracellularly. The decreased level of taurine indicated that brain tissues of cerebral ischemia and reperfusion rats produce excitotoxic neurotoxicity. Hua Liu et al. \[[@B32-molecules-23-01315]\] found that taurine had the effect of an anti-free radical on cerebral ischemic reperfusion damage. Zhong Yang et al. \[[@B33-molecules-23-01315]\]. demonstrated that TCDCA had the effects of downregulating the level of malondialdehyde (MDA) and upregulating the level of glutathione peroxidase (GSH-Px) in MCAO/R rats.

Our results showed that the level of [l]{.smallcaps}-valine was decreased in MCAO/R rats and the levels of isoleucine, [l]{.smallcaps}-leucine, [l]{.smallcaps}-phenylalanine, and L-tryptophan were increased with the treatment of KDZI. Similarly, Liu Siyi et al. \[[@B34-molecules-23-01315]\] also found the biosynthesis of phenylalanine and tryptophan in rats with the treatment of Kudiezi injection. These amino acids enter the tricarboxylic acid cycle by deamination or transamination and promote the production of adenosinetriphosphate (ATP). Changes of these amino acid levels cause the reduction of ATP provided by tricarboxylic acid cycle. Brain cells are highly dependent on mitochondrial energy. Thus, the decrease of ATP provided by the tricarboxylic acid cycle can cause brain ischemia. When cerebral ischemia occurs, oxygen cannot be adequately supplied, the brain tissues of rats are mainly supplied by anaerobic glycolysis, and amino acid contents are significantly reduced. Interestingly, these amino acids can be regulated by the treatment of KDZI. As depicted in [Figure 7](#molecules-23-01315-f007){ref-type="fig"}B, the levels of isoleucine, l-leucine, l-phenylalanine, and l-tryptophan were significantly decreased, and the level of l-valine was increased in the rats of the MCAO/R group compared with that of the sham group; with the treatment of KDZI, the levels of isoleucine, l-leucine, l-phenylalanine, and l-tryptophan were significantly increased, and the level of l-valine was decreased.

After cerebral ischemia, a large number of free radicals are produced through arachidonic acid (ARA) metabolism and other ways, and these free radicals have neurotoxic actions on intracellular proteins, lipids, and nucleotides, resulting in neurocyte damage. The neurotoxic effects of oxygen radicals can be summarized as follows: (1) they act on polyunsaturated fatty acids, and cause lipid peroxidation; and (2) they induce the crosslink of macromolecules, such as DNA, RNA, polysaccharides, and amino acids, which result in activity reduction/loss of the large molecules. As demonstrated in [Figure 7](#molecules-23-01315-f007){ref-type="fig"}B, the level of ARA was significantly decreased in the rats of the MCAO/R group compared with that of the sham group; with the treatment of KDZI, the level of ARA was significantly increased.

Cerebral ischemia produces a large number of free radicals, and these free radicals attack nerve membranes and blood vessels that are rich in polyunsaturated fatty acids and produce lipid peroxides and hydroperoxides. The loss of the unsaturated fatty acids destruct the integrity of cellular structures. Meanwhile, the membrane permeability, ion transport, and membrane screen function are also severely affected, resulting in cell necrosis. Similarly, we found that the level of ARA in rats of MCAO/R + KDZI group increased significantly.

Twenty-two phosphatidyl ethanolamines (PE), phosphatidyl cholines (PC) were changed in MCAO/R rats compared with the rats in Sham group. Both PE and PC were increased by treating MCAO/R with KDZI. Lecithin can be hydrolyzed to produce glycerol phosphorylcholine (GPC), phosphorylcholine (Pcho), and choline, the phosphorylcholine is hydrolyzed into choline with the catalysis of alkaline phosphatase; at the same time, choline produces phosphorylcholine in an ATP-containing environment and then synthesizes lecithin. The studies of Djuricic et al. \[[@B23-molecules-23-01315]\] showed that, in the case of cerebral ischemia, the content of choline increased with the decreased of level of ATP. Kozuka et al. \[[@B35-molecules-23-01315]\] found that, in the early stage of cerebral ischemia in spontaneous hypertensive rats, the level of choline increased at 1--2 h. The studies showed that, three hours after cerebral ischemia-reperfusion in rats, the membrane phospholipids were largely hydrolyzed. Meanwhile, because of the decrease of ATP in the brain tissues, and the reduction of efficiency of choline synthesizing lecithin, the content of choline saw a significant increase in the left-brain tissues of MCAO/R rats, and the level of phosphorylcholine decreased.

3.2. Possible Mechanism of Anti-Cerebral Ischaemia Reperfusion Effect KDZI {#sec3dot2-molecules-23-01315}
--------------------------------------------------------------------------

The profile of metabolic network including the 32 significantly changed metabolites in plasma were shown in [Figure 7](#molecules-23-01315-f007){ref-type="fig"}A, B. This anti-cerebral ischemia reperfusion mechanism of KDZI can be described as below: KDZI has the effect on regulating the levels of [l]{.smallcaps}-valine, isoleucine, [l]{.smallcaps}-phenylalanine, and leucine to enter the tricarboxylic acid cycle by deamination or transamination and promote the production of ATP to provide energy for the brain and anti-cerebral ischemia. KDZI can increase ARA by regulating calcium and sodium ions and NMDARs, resulting in elevated PE, PC, and improved cerebral ischemia. On the other hand, glutamate affects 5-HT secretion, KDZI can decrease 5-HIAA secretion and improve cerebral ischemia.

4. Materials and Methods {#sec4-molecules-23-01315}
========================

4.1. Chemicals and Reagents {#sec4dot1-molecules-23-01315}
---------------------------

Kudiezi injection (KDZI, Lot No. 140506, Jilin Tonghua Huaxia Pharmaceutical Co., Ltd., Tonghua, China), acetonitrile, methanol, and formic acid (HPLC grade) were purchased from Thermo Scientific (Waltham, MA, USA). Trypsin (mass spectrometry grade) was from Promega (Madison, WI, USA). Double distilled water (18.2 MΩ·cm) was from a Milli-Q system (Millipore, Bedford, MA, USA).

4.2. Animals and Grouping {#sec4dot2-molecules-23-01315}
-------------------------

Male Sprague Dawley rats (220 g ± 20 g) were purchased from Beijing SiBeiFu Animal Technology Co. Ltd. (Beijing, China; certification number: SCXK (Jing): 2016-0002). The rats were housed in the clean level condition animal housing facilities (certification number SYXK (Jing) 2016-0038) of BUCM, at a temperature of 22 ± 1 °C, a humidity of 55 ± 5%, and a 12 h light/dark cycle with free access to tap water and chow. All the protocols were reviewed and approved by the Animal Care Committee of BUCM, China. The animals were allowed to acclimatize for a week while being fed with a standard diet and water ad libitum before experiments. Then they were randomly divided into three groups: sham group (SHAM), ischemic group (MCAO/R), and Kudiezi injection group (KDZI), with 15 rats in each group. In the MCAO/R and KDZI groups, rats were subjected to MCAO/R on the right hemisphere of the brain. The animals in the KDZI group were treated with KDZI injection (4.2 mL/kg i.p. The SHAM and MCAO/R groups received 0.9% sodium chloride at 4.2 mL/kg, i.p.).

4.3. Middle Cerebral Artery Occlusion {#sec4dot3-molecules-23-01315}
-------------------------------------

Rats were anesthetized with 10% chloral hydrate (3.5 mL/kg body weight) intraperitoneally. Cerebral ischemia was conducted according to the method by Longa et al. \[[@B36-molecules-23-01315],[@B37-molecules-23-01315]\] with some modifications. A 2-mm nylon monofilament (Guangzhou Jialing Company, Guangzhou, China) was inserted into the internal carotid artery through a small incision on the common carotid artery and advanced 18 ± 2 mm to occlude the middle cerebral artery, until a slight resistance was felt. Two hours after the induction of ischemia, the filament was slowly withdrawn, and the animals were returned to their cages for a period of 2 h of reperfusion. Throughout the procedure, the body temperature was maintained at 37 °C, with a thermostatically-controlled infrared lamp. Rats in the sham group underwent the same procedure without monofilament insertion.

4.4. The Stainings of TTC and H&E {#sec4dot4-molecules-23-01315}
---------------------------------

After 7 days of KDZI administration, the rats were anesthetized with 10% chloral hydrate (3.5 mL/kg body weight). Coronal sections of brains (2 mm) were immersed in 1% 2,3,5-triphenyltetrazolium chloride (TTC) in phosphate buffer saline (pH 7.4) at 37 °C for 15 min and then fixed with 10% paraformaldehyde for 10 min \[[@B38-molecules-23-01315],[@B39-molecules-23-01315]\]. The white color represented infarct tissue and the red color represented normal tissue. TTC-stained sections were photographed and the images were analyzed using Image-Pro Plus 6.0 to calculate the infarct area. Hematoxylin and eosin (H and E) staining was conducted according to the protocol of Xiaoli Yan et al. \[[@B40-molecules-23-01315]\]. Images were captured using an Olympus BX53 microscope (Tokyo, Japan) and analyzed using Image-Pro Plus 6.0 to calculate the IOD value.

4.5. Plasma Pretreatment and UHPLC-LTQ/Orbitrap Analysis {#sec4dot5-molecules-23-01315}
--------------------------------------------------------

After the last administration, rats were anesthetized with 10% chloral hydrate (3.5 mL/kg body weight). Blood was collected from the abdominal aorta and blood samples were collected in tubes containing sodium heparin and centrifuged for 3500 rpm, 10 min at 4 °C. The plasma was removed and placed in aliquots, stored at −80 °C until measurement.

Plasma sample preparation was carried out by protein precipitation with acetonitrile. Four-hundred microliters of precipitant (V (acetonitrile): V (methanol) = 3:1) was added to 200 μL of plasma and the mixture was vortexed for 2 min. After 10 min, the mixture was centrifuged at 10,000 rpm for 15 min at 4 °C. Then the supernatant was transferred and dried on a nitrogen blower. Finally, the dried supernatant was re-dissolved in 100 μL mobile phase (A phase 0.1% formic acid aqueous solution). To validate the analytical methodology, pooled QC samples were prepared by mixing all of the samples. Five QC samples were analyzed before sample sequencing, and during the analysis of the sample sequence, one QC sample was run after every five injections \[[@B41-molecules-23-01315],[@B42-molecules-23-01315]\]. Metabolomics analysis was performed on a Thermo Scientific Dionex Utimate 3000 UHPLC Plus Focused coupled to a LTQ/Orbitrap MS system equipped with an electrospray ionization source operating. A 2.1 × 100 mm BEH 1.7 μm C18 column was equipped for all analyses. The measuring method of biomarkers was from reported research \[[@B43-molecules-23-01315],[@B25-molecules-23-01315]\]. The injection volume was 2 μL, the flow rate was 230 μL/min, the column temperature was 30 °C. The mobile phase was a mixture of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). Ion source temperature: 350 °C, ionization source voltage: 4 KV, capillary voltage: 35 V, tube lens voltage: 110 V, sheath gas and auxiliary gas are high-purity nitrogen (purity \> 99.99%), sheath gas flow rate: 40 arb, the auxiliary air flow rate was 20 arb. Data were acquired using Fourier transform high resolution full sweep (TF, Full scan, Resolution 30000), MS/MS uses data-dependent acquisition, and the broken way is CID. Metabolic profiles were acquired within the range of *m*/*z* 50--1500.

The Proportion of Mobile Phase B Was Optimized as Follows:

Positive ion mode: 0--4 min, 5--7%; 4--5 min, 7--12%; 5--6 min, 12--15%; 6--8 min, 15--30%; 8--17 min 30--48%; 17--21 min, 48--49%; 21--30 min, 49--59%; 30--33 min, 59--61%; 33--35 min, 61--80%; 35--36 min, 80--5%; 36--39 min, 5--5%.

Negative ion mode: 0--3 min, 3--5%; 3--4 min, 5--30%; 4--20 min, 30--36%; 20--21 min, 36--42%; 21--22 min, 42--60%; 22--34 min, 60--64%; 34--39 min, 64--80%; 39--39.1 min, 80--3%; 39.1--42 min, 3--3%.

4.6. Data Processing and Analysis {#sec4dot6-molecules-23-01315}
---------------------------------

The raw data analysis for plasma samples were processed using the Sieve software package version 2.1 (Thermo Fisher Scientific Inc., San Jose, CA, USA). Before chemometric analysis, the data from each sample were normalized to the sum of the peak area \[[@B44-molecules-23-01315]\]. The pre-processed data were analyzed by principal component analysis (PCA) and quadrature signal correction partial least squares analysis (OPLS), using SIMCA-P13.0 software (Umetrics). Differential Metabolites Identification Used Compound Discoverer 2.0 for spectral matching, combined with Metlin and HMDB databases. The obtained differential components were analyzed by MeV (Multi Experiment Viewer, v4.8, TIGR) for hierarchical clustering analysis and K-mean clustering analysis. All experimental data were expressed as means ± SD, and examined by one-way ANOVA test in the SPSS version 16 software package to calculate the statistical significance. *p*-values \< 0.05 were considered significant. Differences in metabolic function and pathway enrichment analysis were using KEGG (<http://www.genome.jp/kegg/>), MBRole (<http://csbg.cnb.csic.es/mbrole2/>), and Metpa ([http: // Metpa.metabolomics.ca](http: // Metpa.metabolomics.ca)), as well as other online tools.

5. Conclusions {#sec5-molecules-23-01315}
==============

In summary, plasma metabolomics analysis of LC-MS provides biomarkers for cerebral ischemia-reperfusion metabolism. Our data shows that amino acid metabolism, energy metabolism, and lipid metabolism are involved in the metabolic pathway of cerebral ischemia and reperfusion. Among them, amino acids are the most important features of cerebral ischemia-reperfusion injury, and are considered to be an important regulator to regulate cell signal transduction. The results also show that taurine and arachidonic acid can be considered as a marker for the diagnosis of clinical diagnostic markers, and LC-MS-based techniques provide a method for the analysis of cerebral ischemia-reperfusion through biological pathways. In the course of the experimental study, further studies are needed to examine the dynamic trends of these biomarkers and the functions of these biomarkers.

**Sample Availability:** Samples of the compounds used in the study are available from the authors.
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![The representative images of HE (**A**) and TTC (**B**,**C**) stainings of brain sections showing the neuroprotective effect of KDZI on focal cerebral ischemia. The place marked by ① in [Figure 1](#molecules-23-01315-f001){ref-type="fig"}A indicates cytoclasis and ② indicates the karyopyknosis of the cortex of the brains in MCAO/R rats. ③ indicates brain edema was significantly alleviated and ④ indicates the neuronal cells almost returned to normal. [Figure 1](#molecules-23-01315-f001){ref-type="fig"}B shows: (**a**) the sham group; (**b**) MCAO/R group; and (**c**) MCAO/R + KDZI group. Data are presented as mean ± SD. ^\#\#^ *p* \< 0.05 with the sham group, \*\* *p* \< 0.05 compared with MCAO/R group.](molecules-23-01315-g001){#molecules-23-01315-f001}

![Representative UPLC-HR-MS total ion chromatograms (TICs) of serum samples from ESI^+^ model (**A**), intensity of TIC = 2.36 × 10^8^; and ESI^−^ model (**B**), intensity of TIC = 6.42 × 10^7^.](molecules-23-01315-g002){#molecules-23-01315-f002}

![Multivariate data analysis of LC-MS in plasma obtained from sham, MCAO/R, and MCAO/R + KDZI group rats. (**A**,**E**) are principal component analysis (PCA) score plots for the components indicating the separation among the three groups; (**B**,**F**) are score scatter plots generated from partial least squares discriminate analysis (PLS-DA); (**C**,**G**) are S-plot of PLS-DA explaining the separation of (**A**,**E**) (variable importance in the projection(VIP) \> 1.0 have been marked); and (**D**,**H**) are the statistical validation of the PLS-DA model by permutation testing. (**A**--**D**) were under positive ion mode; and (**E**--**H**) were under negative ions mode.](molecules-23-01315-g003){#molecules-23-01315-f003}

![Heatmap of the 32 identified metabolites showing a significant difference among samples from the sham, MCAO/R, and MCAO/R + KDZI groups constructed by using by using the software Multi Experiment Viewer (MeV) v4.8. Rows: potential biomarkers; columns: samples. The color key indicates the relative amounts of metabolites: Light green represents the lowest; light red represents the highest.](molecules-23-01315-g004){#molecules-23-01315-f004}

![(**A**) Fragmentation pathway and product ion spectrum of L-phenylalanine; (**B**) MS/MS spectrum of [l]{.smallcaps}-phenylalanine by mzCloud.](molecules-23-01315-g005){#molecules-23-01315-f005}

![The metabolic pathways related to cerebral ischemia-reperfusion, as analyzed by MetaboAnalyst.](molecules-23-01315-g006){#molecules-23-01315-f006}

![(**A**) Possible mechanism of anti-cerebral ischaemia reperfusion effect KDZI. (**B**) Typical metabolite variations in plasma samples from sham, MCAO/R, and MCAO/R + KDZI. Glu, glutamate; CoA, acetyl coenzyme A; ARA, arachidonate; 5-HT, 5-hydroxytryptamine; CAM, calmodulin; PE and PC, phospholipid; NMDARs, *N*-methyl-[D]{.smallcaps}-aspartic acid receptors.](molecules-23-01315-g007){#molecules-23-01315-f007}

molecules-23-01315-t001_Table 1

###### 

The analytical performance of the UPLC-MS method (*n* = 6).

  t~R~-*m/z*      Precision (*RSD*, %)   Stability (*RSD*, %)   Repeatability (*RSD*, %)                 
  --------------- ---------------------- ---------------------- -------------------------- ------ ------ ------
  **Positive**                                                                                           
  2.99--453.34    0.25                   3.41                   1.88                       7.70   0.59   6.51
  5.38--215.01    0.08                   7.10                   0.33                       7.28   0.20   6.98
  9.89--319.23    0.17                   5.80                   0.13                       3.72   0.17   6.51
  14.38--582.38   0.14                   5.35                   0.23                       6.22   0.28   4.52
  17.44--255.23   0.035                  5.14                   0.09                       6.89   0.04   5.11
  **Negative**                                                                                           
  0.79--269.0     0.65                   7.49                   0.56                       7.07   0.56   6.83
  11.33--544.34   0.09                   4.99                   0.07                       4.23   0.09   4.99
  12.06--478.34   0.15                   2.91                   0.14                       2.30   0.15   3.45
  14.63--341.32   0.11                   7.33                   0.12                       6.31   0.11   8.33
  19.42--654.33   0.03                   4.94                   0.08                       5.91   0.08   6.44

Note: t~R~: Retention time.

molecules-23-01315-t002_Table 2

###### 

Potential plasma biomarkers detected by LC-MS and their intensities in the sham, MCAO/R, and MCAO/R + KDZI groups analyzed by one-way ANOVA.

  No.   t~R~     *m/z*      Formula              Identification                          Adduct Type     Flod Change   
  ----- -------- ---------- -------------------- --------------------------------------- --------------- ------------- ------
  1     0.93     118.0856   C~5~H~11~NO~2~       L-Valine                                M + H           1.40          0.65
  2     1.617    132.1013   C~6~H~13~NO~2~       Isoleucine                              M + H           0.68          1.47
  3     2.829    166.0856   C~9~H~11~NO~2~       L-Phenylalanine                         M + H           0.66          1.45
  4     5.51     205.0965   C~11~H~12~N~2~O~2~   L-Tryptophan                            M + H           0.81          1.36
  5     1.89     192.0655   C~10~H~9~NO~3~       5-Hydroxyindole-3-acetic acid           M + H           1.34          0.64
  6     8.585    132.1013   C~6~ H~13~ NO~2~     Leucine                                 M + H           0.68          1.44
  7     28.55    480.28     C~26~H~45~NO~6~S     Taurochenodesoxycholic acid             M - H~2~O - H   0.71          1.43
  8     143      283.2623   C~18~H~34~O~2~       Oleic acid                              M - H           0.78          1.56
  9     33.932   305.2468   C~20~H~32~O~2~       Arachidonic acid                        M + H           0.63          1.27
  10    35.14    283.2623   C~18~H~36~O~2~       Stearic acid                            M - H           0.71          1.39
  11    23.119   468.3067   C~22~H~46~NO~7~P     PE (17:0/0:0)                           M + H           0.61          1.38
  12    26.884   482.3222   C~23~H~48~NO~7~P     LysoPE (0:0/18:0)                       M + H           0.81          1.34
  13    37.372   482.3221   C~23~H~48~NO~7~P     LysoPE (18:0/0:0)                       M + H           0.51          1.31
  14    25.379   482.3225   C~23~H~48~NO~7~P     LysoPC (15:0)                           M + H           0.61          1.20
  15    29.152   496.3376   C~24~H~50~NO~7~P     LysoPC (16:0)                           M + H           0.78          1.45
  16    33.86    508.3738   C~26~H~54~NO~6~P     LysoPC (p-18:0)                         M + H           0.81          1.29
  17    34.499   510.3526   C~25~H~52~NO~7~P     LysoPE (0:0/20:0)                       M + H           0.74          1.32
  18    32.943   510.3526   C~25~H~52~NO~7~P     LysoPC (17:0)                           M + H           0.69          1.42
  19    24.784   518.3221   C~26~H~48~NO~7~P     LysoPC (18:3(6z, 9z, 12z))              M + H           0.89          1.23
  20    29.081   518.32     C~26~H~48~NO~7~P     PC(18:3(9z, 12z, 15z)/0:0)              M + H           0.82          1.42
  21    31.039   522.3535   C~26~H~52~NO~7~P     LysoPC (18:1(9z))                       M + H           0.71          1.28
  22    33.776   522.3535   C~26~H~52~NO~7~P     LysoPC (18:1(11z))                      M + H           0.63          1.32
  23    15.814   536.333    C~27~H~54~NO~7~P     LysoPE (0:0/22:1(13z))                  M + H           0.89          1.41
  24    17.288   536.3331   C~27~H~54~NO~7~P     LysoPE (22:1(13z)/0:0)                  M + H           0.71          1.24
  25    35.514   536.3695   C~27~H~54~NO~7~P     LysoPE (0:0/22:1(13Z))                  M + H           0.83          1.42
  26    32.715   538.3848   C~27~H~56~NO~7~P     LysoPE (0:0/22:0)                       M + H           0.79          1.23
  27    30.365   538.3858   C~27~H~56~NO~7~P     LysoPE (22:0/0:0)                       M + H           0.70          1.32
  28    24.365   542.3221   C~28~H~48~NO~7~P     LysoPC (20:5(5z, 8z, 11z, 14z, 17z))    M + H           0.61          1.33
  29    30.525   546.3532   C~28~H~52~NO~7~P     LysoPC (20:3(5z, 8z, 11z))              M + H           0.74          1.34
  30    29.248   546.3534   C~28~H~52~NO~7~P     LysoPC (20:3(8z, 11z, 14z))             M + H           0.82          1.31
  31    34.412   548.369    C~28~H~54~NO~7~P     LysoPC (20:2(11z, 14z))                 M + H           0.82          1.34
  32    29.521   570.3532   C~30~H~52~NO~7~P     LysoPC (22:5(7z, 10z, 13z, 16z, 19z))   M + H           0.81          1.34

Note: t~R~: Retention time.

molecules-23-01315-t003_Table 3

###### 

The information of the relevant metabolic pathways.

  Pathyway Name                                     In Set   *p*-Value (×10^3^)   *FDR* Correction (×10^3^)
  ------------------------------------------------- -------- -------------------- ---------------------------
  Tryptophan metabolism                             2        0                    0
  Fatty acid elongation unsaturated                 3        0.00000296           0.0000266
  Biosynthesis of unsaturated fatty acids           3        0.00000723           0.000803
  Valine, leucine and isoleucine degradation        3        0.0000744            0.00156
  Valine, leucine and isoleucine biosynthesis       3        0.000422             0.00814
  Aminoacyl-tRNA biosynthesis                       4        0.00119              0.044
  Biosynthesis of secondary metabolites             5        0.00157              0.0173
  Glucosinolate biosynthesis                        5        0.0332               0.38
  Metabolic pathways                                3        0.116                0.522
  jasmonoyl-amino acid conjugates biosynthesis I    4        3.29                 7.4
  jasmonoyl-amino acid conjugates biosynthesis II   3        6.53                 28.3

[^1]: These authors contributed equally to this work.
